Patent ID: 6500813
Filing Date: 2002-12-31
Classification: A61K,A61P,Y10S

Abstract:
A method comprising administering an ophthalmic composition to an eye, said composition comprising active vitamin D, wherein said composition is administered in an amount sufficient to prevent deterioration of at least one of the following:(i) optical transparency, observed after an ophthalmic operation, in the course of the healing process, (ii) occurrence of high intraocular pressure disease, observed after an ophthalmic operation, in the course of the healing process, (iii) defective sight, observed after an ophthalmic operation, in the course of the healing process, (iv) optical transparency or defective sight of a transparent body of a human eye, observed after an ophthalmic operation of the anterior ocular region of the human eye, due to hyperplasia of the anterior ocular cells which are in the healing process of the tissues damaged by the operation and/or excess production of cellular materials, (v) optical transparency of intraocular transparent bodies due to intraocular inflammation caused by an inflammatory disease in the anterior ocular region of human eyeball, (vi) high intraocular pressure disease due to intraocular inflammation caused by an inflammatory disease in the anterior ocular region of human eyeball, or in an amount sufficient to control at least one of the following:(vii) any hyperplasia of inflammatory cells present in the aqueous humor and lens epithelial cells during healing of the tissues damaged by an ophthalmic operation for the anterior ocular region and/or any excess production of cellular materials to maintain the transparency of the anterior ocular region of the eyeball and the normal intraocular pressure, (viii) hyperplasia of corneal epithelial cells and keratocytes during healing of the tissues damaged by an ophthalmic operation for cornea and/or excess production of cellular materials to maintain the optical transparency and normal refractive power of the cornea.